Safety and Immunogenicity of a Single Oral Dose of Recombinant Double Mutant Heat-Labile Toxin Derived from Enterotoxigenic Escherichia coli

A Double Mutant Heat-Labile Toxin from Escherichia coli, LT(R192G/L211A), Is an Effective Mucosal Adjuvant for Vaccination against Helicobacter pylori Infection

(2013) Louise Sjökvist Ottsjö et al.   INFECTION AND IMMUNITY

Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant

(2013) J. Holmgren et al.   VACCINE

Progress and hurdles in the development of vaccines against enterotoxigenicEscherichia coliin humans

(2012) Weiping Zhang et al.   Expert Review of Vaccines

The Adjuvant Double Mutant Escherichia coli Heat Labile Toxin Enhances IL-17A Production in Human T Cells Specific for Bacterial Vaccine Antigens

(2012) Susannah Leach et al.   PLoS One

Characterization of a Mutant Escherichia coli Heat-Labile Toxin, LT(R192G/L211A), as a Safe and Effective Oral Adjuvant

(2011) Elizabeth B. Norton et al.   Clinical and Vaccine Immunology

A systematic review of ETEC epidemiology focusing on colonization factor and toxin expression

(2011) S.D. Isidean et al.   VACCINE

Non-toxic derivatives of LT as potent adjuvants

(2010) Vanusa P. da Hora et al.   VACCINE

Toxin-Mediated Effects on the Innate Mucosal Defenses: Implications for Enteric Vaccines

(2009) G. M. Glenn et al.   INFECTION AND IMMUNITY

Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin

(2009) Nancy A. Summerton et al.   VACCINE